Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20–26 years)
Open Access
- 16 September 2015
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 11 (10) , 2337-2344
Abstract
There is some concern about the effectiveness of the HPV vaccine among young adult women due to the risk of prior HPV infection. This study used National Health and Nutrition Examination Survey (NHANES) 2007–2012 data to evaluate the effectiveness of HPV vaccination among women 20–26 years of age who were vaccinated after 12 years of age. This cross-sectional study examined 878 young adult women (20–26 years) with complete information on HPV prevalence and HPV vaccination status from NHANES 2007–2012. Vaginal swab specimens were analyzed for HPV DNA by L1 consensus polymerase chain reaction followed by type-specific hybridization. Multivariate logistic regression models controlling for sociodemographic characteristics and sexual behaviors were used to compare type-specific HPV prevalence between vaccinated and unvaccinated women. A total of 21.4% of young adult women surveyed through NHANES between 2007 and 2012 received the HPV vaccine. Vaccinated women had a lower prevalence of vaccine types than unvaccinated women (7.4% vs 17.1%, prevalence ratio 0.43, 95% CI 0.21–0.88). The prevalence of high-risk nonvaccine types was higher among vaccinated women than unvaccinated women (52.1% vs 40.4%, prevalence ratio 1.29, 95% CI 1.06–1.57), but this difference was attenuated after adjusting for sexual behavior variables (adjusted prevalence ratio 1.19, 95% CI 0.99–1.43). HPV vaccination was effective against all 4 vaccine types in young women vaccinated after age 12. However, vaccinated women had a higher prevalence of high-risk nonvaccine types, suggesting that they may benefit from newer vaccines covering additional types.Keywords
This publication has 32 references indexed in Scilit:
- Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010The Journal of Infectious Diseases, 2013
- A Murine Genital-Challenge Model Is a Sensitive Measure of Protective Antibodies against Human Papillomavirus InfectionJournal of Virology, 2011
- Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose scheduleHuman Vaccines, 2011
- HPV Vaccine against Anal HPV Infection and Anal Intraepithelial NeoplasiaNew England Journal of Medicine, 2011
- Prevalence of Genital Human Papillomavirus Among Females in the United States, the National Health and Nutrition Examination Survey, 2003–2006The Journal of Infectious Diseases, 2011
- Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide studyThe Lancet Oncology, 2010
- In Vivo Mechanisms of Vaccine-Induced Protection against HPV InfectionCell Host & Microbe, 2010
- Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trialBMJ, 2010
- The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16–26 YearsThe Journal of Infectious Diseases, 2009
- A review of human carcinogens—Part B: biological agentsThe Lancet Oncology, 2009